Università degli Studi di Napoli 'Federico II', c/o AOU Federico II
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Saccà, Francesco
RFC1-NHS, NCT05177809: RFC1 Natural History Study

Recruiting
N/A
150
Europe, RoW
Clinical rating scale to measure ataxia disease severity and progression, Scale for the Assessment and rating of Ataxia (SARA)
Prof. Dr. Matthis Synofzik
Ataxia
12/24
12/25
Pane, Chiara
RFC1-NHS, NCT05177809: RFC1 Natural History Study

Recruiting
N/A
150
Europe, RoW
Clinical rating scale to measure ataxia disease severity and progression, Scale for the Assessment and rating of Ataxia (SARA)
Prof. Dr. Matthis Synofzik
Ataxia
12/24
12/25
Alves, Paula
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
RFC1-NHS, NCT05177809: RFC1 Natural History Study

Recruiting
N/A
150
Europe, RoW
Clinical rating scale to measure ataxia disease severity and progression, Scale for the Assessment and rating of Ataxia (SARA)
Prof. Dr. Matthis Synofzik
Ataxia
12/24
12/25

Download Options